[{"orgOrder":0,"company":"Shenzhen Hepalink Pharmaceutical","sponsor":"Orient EuroPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen Hepalink Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shenzhen Hepalink Pharmaceutical \/ Orient EuroPharma","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen Hepalink Pharmaceutical \/ Orient EuroPharma"}]

Find Clinical Drug Pipeline Developments & Deals by Shenzhen Hepalink Pharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : Under the agreement, OncoVent agreed to grant exclusive rights to OEP, which will be responsible for the commercialization of MAb-B43.13 (oregovomab), an immunotherapy drug candidate, in Taiwan, including related regulatory applications and necessary cli...

                          Product Name : MAb-B43.13

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          March 28, 2023

                          Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Orient EuroPharma

                          Deal Size : $11.2 million

                          Deal Type : Licensing Agreement

                          blank